Novo Nordisk (NVO) total liabilities
Novo Nordisk (NVO) had total liabilities of DKK 348.86B at the end of fiscal 2025 (December 31, 2025). That is 8.3% higher than the DKK 322.14B of fiscal 2024. Figures as of 18 Nov 2026, 20:14 UTC, from Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- DKK 348.86B
- Change on fiscal 2024
- +8.3%
- Highest on record
- DKK 348.86Bfiscal 2025
- Lowest on record
- DKK 157.77Bfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in DKK. Figures, not advice.
Novo Nordisk total liabilities, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was DKK 348.86B in fiscal 2025 and the lowest DKK 157.77B in fiscal 2022.
Total liabilities by fiscal year
Novo Nordisk total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | DKK 348.86B | 8.3% up | |
| 2024 | DKK 322.14B | 54.9% up | |
| 2023 | DKK 207.93B | 31.8% up | |
| 2022 | DKK 157.77B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Gilead Sciences GILD | $36.41B | 2025 |
| Abbott Laboratories ABT | $33.94B | 2025 |
| Novo Nordisk NVO | DKK 348.86B | 2025 |
| Pfizer PFE | $121.39B | 2025 |
| Danaher DHR | $30.92B | 2025 |
| Intuitive Surgical ISRG | $2.52B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Novo Nordisk, figure by figure
- Novo Nordisk market cap
- Novo Nordisk revenue
- Novo Nordisk earnings
- Novo Nordisk earnings per share (EPS)
- Novo Nordisk P/E ratio
- Novo Nordisk P/S ratio
- Novo Nordisk P/B ratio
- Novo Nordisk free cash flow
- Novo Nordisk operating margin
- Novo Nordisk dividend
- Novo Nordisk shares outstanding
- Novo Nordisk total debt
- Novo Nordisk cash on hand
- Novo Nordisk total assets
- Novo Nordisk net assets (shareholders' equity)
- Novo Nordisk return on equity (ROE)
- Novo Nordisk return on invested capital (ROIC)
Novo Nordisk (NVO) overview: price, valuation and scorecardAll health care companies by market value
Novo Nordisk total liabilities: questions and answers
How large are Novo Nordisk's total liabilities?
Novo Nordisk (NVO) had total liabilities of DKK 348.86B at the end of fiscal 2025 (December 31, 2025). That is 8.3% higher than the DKK 322.14B of fiscal 2024.
What are the highest and lowest total liabilities figures on record for Novo Nordisk?
Across the 4 fiscal years on record (2022–2025), the highest was DKK 348.86B in fiscal 2025 and the lowest DKK 157.77B in fiscal 2022.
How is Novo Nordisk's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Novo Nordisk it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Novo Nordisk (NVO) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/NVO/total-liabilities
Underlying data: Yahoo Finance.